Call Options

15 transactions
Quarter Operation Price Per call calls change calls Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$15.61 - $23.34 $4.16 Million - $6.23 Million
266,800 New
266,800 $4.17 Million
Q1 2022

May 17, 2022

SELL
$60.15 - $84.52 $493,230 - $693,064
-8,200 Reduced 8.94%
83,500 $6.92 Million
Q4 2021

Feb 15, 2022

BUY
$75.08 - $121.99 $1.55 Million - $2.53 Million
20,700 Added 29.15%
91,700 $6.89 Million
Q3 2021

Nov 16, 2021

BUY
$116.17 - $194.55 $511,148 - $856,020
4,400 Added 6.61%
71,000 $8.25 Million
Q2 2021

Aug 16, 2021

SELL
$130.4 - $225.58 $1.38 Million - $2.39 Million
-10,600 Reduced 13.73%
66,600 $14.8 Million
Q1 2021

May 18, 2021

SELL
$124.11 - $190.17 $15.6 Million - $23.9 Million
-125,700 Reduced 61.95%
77,200 $10.2 Million
Q4 2020

Feb 17, 2021

SELL
$112.16 - $174.14 $257,968 - $400,521
-2,300 Reduced 1.12%
202,900 $35.1 Million
Q3 2020

Nov 17, 2020

BUY
$58.05 - $111.31 $8.72 Million - $16.7 Million
150,300 Added 273.77%
205,200 $22.8 Million
Q2 2020

Aug 17, 2020

SELL
$57.2 - $74.41 $3.03 Million - $3.94 Million
-53,000 Reduced 49.12%
54,900 $3.26 Million
Q1 2020

May 15, 2020

SELL
$57.05 - $95.75 $1.69 Million - $2.84 Million
-29,700 Reduced 21.58%
107,900 $7.27 Million
Q4 2019

Feb 14, 2020

SELL
$68.3 - $93.8 $4.61 Million - $6.33 Million
-67,500 Reduced 32.91%
137,600 $11.6 Million
Q3 2019

Nov 14, 2019

BUY
$61.86 - $97.8 $556,740 - $880,200
9,000 Added 4.59%
205,100 $15.3 Million
Q2 2019

Aug 15, 2019

BUY
$42.22 - $63.23 $4.05 Million - $6.07 Million
96,000 Added 95.9%
196,100 $12.4 Million
Q1 2019

May 16, 2019

SELL
$31.96 - $56.12 $1.79 Million - $3.14 Million
-56,000 Reduced 35.87%
100,100 $4.82 Million
Q3 2017

Nov 14, 2017

BUY
$18.05 - $21.75 $2.82 Million - $3.4 Million
156,100
156,100 $3.1 Million

Others Institutions Holding NVCR

About NovoCure Ltd


  • Ticker NVCR
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Medical Instruments & Supplies
  • Shares Outstandng 104,950,000
  • Market Cap $2.57B
  • Description
  • NovoCure Limited, an oncology company, engages in the development, manufacture, and commercialization of tumor treating fields (TTFields) devices for the treatment of solid tumor cancers in the United States, Europe, the Middle East, Africa, Japan, and Greater China. Its TTFields devices include Optune for the treatment of glioblastoma; and Optu...
More about NVCR
Track This Portfolio

Track Jane Street Group, LLC Portfolio

Follow Jane Street Group, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Jane Street Group, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Jane Street Group, LLC with notifications on news.